Mood Change in a Patient with a Carcinoid Tumor

Sierzchula, Jessica J; MacGregor, Robert M.; Onuscheck, Douglas S; Slyke, John A. Van; Tavakoli, Hamid

doi:10.3928/00485713-20160120-01

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 lists the study and patient characteristics from all studies included in our review. Most of these articles (12 of 15; 80%) reported a single case (Noyer and Schwartz, 1997; Russo et al, 2004; Bajwah and Lee, 2005; Simbera and Balon, 2005; Furse et al, 2008; Seshamani et al, 2009; Yazicioǧlu et al, 2012; Bariani et al, 2013; Nobels et al, 2016; Sierzchula et al, 2016; Magistris and Gamble, 2017; Mehra and Kon, 2017), while the remaining articles (3 of 15; 20%) were comprised of larger case series (Williams and Dolenc, 2005; Shi et al, 2017; Isenberg-Grzeda et al, 2018). Most of the cases identified by our search (149/161; 93%) came from one of the three larger case series.…”

Section: Resultsmentioning

confidence: 99%

Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review

et al. 2020

View full text Add to dashboard Cite

Objective Symptoms of depression and anxiety are common in neuroendocrine tumor (NET), yet controversy exists over whether serotonin-mediated antidepressants (SAs) are safe in this population. We sought to address this knowledge gap. Method Following PRISMA guidelines, we conducted a systematic review to identify NET patients who were prescribed SA. Results We identified 15 articles, reporting on 161 unique patients, 72 with carcinoid syndrome (CS) and 89 without. There was substantial agreement between reviewers at the full-text stage (κ = 0.69). Three of the articles, all with low risk of bias, accounted for most of the cases (149/161; 93%). Among the 72 NET patients with CS prior to antidepressant usage, CS was exacerbated in 6 cases (8%), only 3 (4%) of whom chose to discontinue the antidepressant. The remaining 89 patients had no prior CS symptoms, and none developed CS following antidepressant usage. Overall, no instances of carcinoid crisis or death were reported. Conclusions We found no evidence for serious adverse outcomes related to SA usage in NET patients. Previous authors have recommended avoiding antidepressants in NET, but our findings do not support those recommendations. Oncologists should nonetheless monitor for symptom exacerbation when prescribing SA to patients with NET.

show abstract

Section: Resultsmentioning

confidence: 99%

Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These findings are in line with an ongoing debate among clinicians and researchers as to whether psychological conditions could be symptoms of CS. Because the condition is rare, a paucity of research exists regarding the emotional symptoms or psychological conditions associated with CS [42][43][44][45].…”

Section: Discussion/conclusionmentioning

confidence: 99%

Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index

et al. 2020

View full text Add to dashboard Cite

Objective: To develop a symptom-focused index to evaluate representative symptoms, treatment side effects, and emotional and functional well-being of patients with carcinoid syndrome (CS). Methods: The development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index (FACT-CSI) followed US Food and Drug Administration guidelines for the development of patient-reported outcome (PRO) measures and involved the following: (a) literature review; (b) interviews with 14 CS patients; (c) interviews with 9 clinicians; and (d) instrument development involving input from a range of PRO measure development and CS experts. The resulting draft instrument underwent cognitive interviews with 7 CS patients. Results: Forty-six CS sources were reviewed. Analysis of patient interviews pro-duced 23 patient-reported symptoms. The most frequently endorsed physical symptoms were flushing, diarrhea, abdominal pain, fatigue, and food sensitivity/triggers. Seven priority CS emotional and functional themes were also identified by patients. Expert interviews revealed 12 unique priority symptoms -the most common being diarrhea, flushing, wheezing, edema, abdominal pain/cramping, fatigue, and 8 emotional and functional concerns. Through an iterative process of team and clinical collaborator meetings, data review, item reduction and measure revision, 24 items were selected for the draft symptom index representing symptoms, emotional concerns, global assessment of treatment side effects, and functional well-being. Cognitive interview results demonstrated strong content validity, including positive endorsement of item clarity (>86% across items), symptom relevance (>70% for most items), and overall measure content (86%). Conclusions: The FACT-CSI is a content-relevant, symptom-focused index reflecting the highest priority and clinically relevant symptoms and concerns of people with CS.

show abstract

“…1 Although infrequent, their incidence has been increasing in the recent decades, 2 currently 2 per 100 000 inhabitants. 3 About 30% are functionally active due to the release of biogenic amines into the bloodstream, giving rise to carcinoid syndrome. 2,4 Cancer patients are more likely to have psychiatric comorbidities compared to the general population.…”

Section: Introductionmentioning

confidence: 99%

Psicose Orgânica em Doente com Tumor Carcinoide Atípico do Pulmão

Gomes

Santos

Moutinho

et al. 2022

RPPSM

View full text Add to dashboard Cite

Manifestações psiquiátricas estão presentes em pelo menos um terço dos doentes com cancro. Apesar disso, menos de 50% são devidamente acompanhados. Este artigo contribui para a escassa literatura existente sobre sintomas psicóticos em doentes com tumores neuroendócrinos ‐ uma apresentação rara de uma doença rara. Enfatiza uma possível associação entre tumor carcinoide do pulmão e sintomas psicóticos, discute o diagnóstico diferencial e apresenta uma opção terapêutica psicofarmacológica eficaz, nunca publicada, até onde sabemos. Relatamos o caso de uma doente de 69 anos com um tumor carcinoide atípico do pulmão, sem história psiquiátrica prévia. O quadro clínico caracterizou‐se por ideias delirantes paranoides e autoreferenciais, atividade alucinatória acústico‐verbal, humor depressivo e ansiedade extrema secundários. Foi admitida uma psicose orgânica em provável relação com a sua doença neoplásica, que foi tratada com aripiprazol, com boa resposta e tolerância.

show abstract

Mood Change in a Patient with a Carcinoid Tumor

Cited by 3 publications

References 14 publications

Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review

Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review

Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index

Psicose Orgânica em Doente com Tumor Carcinoide Atípico do Pulmão

Contact Info

Product

Resources

About